Advertisement

Dopaminrezeptoragonisten: Der neuroprotektive Ansatz

  • P. Riederer
Chapter

Zusammenfassung

Ergänzend kann man festhalten, daß Dopaminrezeptoragonisten eine direkte Stimulation von Dopaminrezeptorsubtypen ermÖglichen. Damit reduzieren sie die Freisetzung von Dopamin aus präsynaptischen Nervenenden und verringern dadurch mÖglichen oxidativen Streß (Davis et al. 1997, Melamed 1995); zum Beispiel gelingt experimentell die UnterdrÜckung der Impulsrate von dopaminergen Neuronen der Substantia nigra pars compacta durch Pramipexol (Piercey et al. 1996).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bernocchi G, Gerzeli G, Scherini E, Vignola C (1993) Neuroprotective effects of α-dihydro-ergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4phenyl-1,2,3,6-tetrahydropy ridine. Acta Neuropathol 85: 404–413PubMedCrossRefGoogle Scholar
  2. Canonico PL, Sortino MA, Favit A et al. (1993) Dihydroergocryptine protects from acute experimental allergic encephalomyelitis in the rat. Funct Neurol 8: 183–188PubMedGoogle Scholar
  3. Carvey PM, Pieri S, Ling ZD (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104: 209–228PubMedCrossRefGoogle Scholar
  4. Cassels BK, Asencio M, Conget P, Speisky H, Videla LA, Lissi EA (1995) Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmacol Res 31: 103–107PubMedCrossRefGoogle Scholar
  5. Coppi G (1995) Neuroprotective activity of alpha-dihydroergocryptine in animal models. J Neural Transm [Suppl] 45: 307–317Google Scholar
  6. Davis MD, Heffner TG, Cooke LW (1997) Dopamine agonist-induced inhibition of neurotransmitter release from the awake squirrel monkey putamen as measured by microdialysis. J Neurochem 68: 659–666PubMedCrossRefGoogle Scholar
  7. Delbarre B, Delbarre G, Rochat C, Calinon F (1995) Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Mol Chem Neuropathol 26: 43–52PubMedCrossRefGoogle Scholar
  8. Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA (1992) Chronic dietary pergolide preserves nigrostriatal integrity in aged-Fischer-334 rats. Neurobiol Aging 13: 339–351PubMedCrossRefGoogle Scholar
  9. Gassen M, Glinka Y, Pinchasi B, Youdim MB (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219–225PubMedCrossRefGoogle Scholar
  10. Hall E D, Andrus P K, Oostveen J A, Althaus J S, Von Voigtlander PF (1996) Neuroprotective effects of the dopamine D-2/D-3 agonist pramipexole against postischemic or meth-amphetamine-induced degeneration of nigro-striatal neurons. Brain Res 742: 80–88PubMedCrossRefGoogle Scholar
  11. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y (1997) Inhibitory effets of talipexole and pramipexole on MPTP-Induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 74: 51–57PubMedCrossRefGoogle Scholar
  12. Melamed E (1995) Does treatment with dopamine agonists affect utilization of exogenous levo-dopa in the parkinsonian striatum? J Neural Transm [Suppl] 45: 57–60Google Scholar
  13. Nishibayashi S, Asanuma M, Kohno R, Gomez-Vargas M, Ogawa N (1996) Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 67: 2208–2211PubMedCrossRefGoogle Scholar
  14. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxy-dopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207–213PubMedCrossRefGoogle Scholar
  15. Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 810: 27–33PubMedCrossRefGoogle Scholar
  16. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a D3-prefering dopamine agonist: comparison to other dopamine agonists. Eur J Pharmacol 312: 35–44PubMedCrossRefGoogle Scholar
  17. Renodon A, Boncher JL, Sari M A, Delaforge M, Ouazzani J, Mansury D (1997) Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. FEBS Lett 406: 33–36PubMedCrossRefGoogle Scholar
  18. Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm [PD-Sect] 10: 115–127CrossRefGoogle Scholar
  19. Tanaka M, Sotomatsu A, Yoshida T, Hirai S (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron. Neurosci Lett 183: 116–119PubMedCrossRefGoogle Scholar
  20. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034–1038PubMedCrossRefGoogle Scholar
  21. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W (1999) Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Life Sci 64: 1275–1285PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • P. Riederer

There are no affiliations available

Personalised recommendations